NO_LONGER_AVAILABLENot Applicable

An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Plain-language summary

The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data. (NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.Subjects who have completed any BHV3000 (rimegepant) clinical study without significant protocol violations.

Exclusion criteria

✕. History of basilar migraine or hemiplegic migraine
✕. History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease
✕. HIV history
✕. Uncontrolled hypertension or uncontrolled diabetes
✕. Current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
✕. History of gastric, or small intestinal surgery, or has a disease that causes malabsorption

Trial details

NCT IDNCT03934086

SponsorPfizer

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Migraine trials